Ignite Creation Date:
2025-12-24 @ 9:43 PM
Ignite Modification Date:
2026-01-02 @ 3:06 PM
Study NCT ID:
NCT00545532
Status:
COMPLETED
Last Update Posted:
2018-07-12
First Post:
2007-10-16
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Cambodia', 'Greece']}, 'conditionBrowseModule': {'meshes': [{'id': 'D007251', 'term': 'Influenza, Human'}], 'ancestors': [{'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D009976', 'term': 'Orthomyxoviridae Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D053139', 'term': 'Oseltamivir'}], 'ancestors': [{'id': 'D000081', 'term': 'Acetamides'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D053138', 'term': 'Cyclohexenes'}, {'id': 'D003510', 'term': 'Cyclohexanes'}, {'id': 'D003516', 'term': 'Cycloparaffins'}, {'id': 'D006840', 'term': 'Hydrocarbons, Alicyclic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'genentech@druginfo.com', 'phone': '800 821-8590', 'title': 'Medical Communications', 'organization': 'Hoffmann-La Roche'}, 'certainAgreement': {'otherDetails': "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': 'Baseline up to Day 40', 'description': 'The safety population included all participants who received at least one treatment with study medication.', 'eventGroups': [{'id': 'EG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.', 'otherNumAtRisk': 105, 'deathsNumAtRisk': 105, 'otherNumAffected': 23, 'seriousNumAtRisk': 105, 'deathsNumAffected': 0, 'seriousNumAffected': 8}, {'id': 'EG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.', 'otherNumAtRisk': 110, 'deathsNumAtRisk': 110, 'otherNumAffected': 35, 'seriousNumAtRisk': 110, 'deathsNumAffected': 1, 'seriousNumAffected': 10}], 'otherEvents': [{'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 11}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 14}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 10}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 12}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 12}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}], 'seriousEvents': [{'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Bronchopulmonary aspergillosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 2}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Lower respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Oral herpes', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Pulmonary tuberculosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Pyelonephritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Sepsis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Septic shock', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Sinusitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Febrile neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Asthenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Leukaemia recurrent', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Metastases to meninges', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 0}], 'organSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 105, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 110, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 20.0'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants With Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': 'On Treatment', 'categories': [{'measurements': [{'value': '40.0', 'groupId': 'OG000'}, {'value': '47.3', 'groupId': 'OG001'}]}]}, {'title': 'Off Treatment', 'categories': [{'measurements': [{'value': '25.7', 'groupId': 'OG000'}, {'value': '29.1', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Day 40', 'description': 'An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who received at least one dose of study drug and had a safety assessment performed post randomization.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants Who Developed Viral Resistance to Oseltamivir', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': 'Post-BL Phenotypic Resist, >/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.2', 'groupId': 'OG000'}, {'value': '1.3', 'groupId': 'OG001'}]}]}, {'title': 'Post-BL Genotypic Resist, >/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '9.6', 'groupId': 'OG000'}, {'value': '2.6', 'groupId': 'OG001'}]}]}, {'title': 'Post-BL Phenotypic Resist, < 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '25.0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}, {'title': 'Post-BL Genotypic Resist, < 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '25.0', 'groupId': 'OG000'}, {'value': '12.5', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Day 40', 'description': 'Resistance was defined as the presence of oseltamivir resistance mutations in viruses isolated from nasopharyngeal swab samples, identified by sequencing of the neuraminidase (NA) and hemagglutinin (HA) genes (genotypic resistance) and/or determination of the oseltamivir concentration at which the response is reduced by half (IC50) in an NA inhibition assay (phenotypic resistance). Reported are post-baseline phenotypic and genotypic resistance in adults \\>/= 18 years and children and adolescents \\<18 years in the modified Intent-to-Treat infected (mITTi) population.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants With Tissue Rejection or Graft Versus Host Disease (GVHD)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Day 40', 'description': 'The percentage of transplant patients in the safety population who experienced tissue rejection and/or GvHD is reported.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who received at least one dose of study drug and had a safety assessment performed post randomization.'}, {'type': 'SECONDARY', 'title': 'Time to Resolution (TTR) of All Clinical Influenza Symptoms', 'denoms': [{'units': 'Participants', 'counts': [{'value': '82', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': 'Adults >/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}, {'value': '75', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '103.3', 'groupId': 'OG000', 'lowerLimit': '69.0', 'upperLimit': '112.7'}, {'value': '103.6', 'groupId': 'OG001', 'lowerLimit': '57.1', 'upperLimit': '140.0'}]}]}, {'title': 'Adults and adolescents >/= 13 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '75', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '103.4', 'groupId': 'OG000', 'lowerLimit': '75.4', 'upperLimit': '122.7'}, {'value': '107.2', 'groupId': 'OG001', 'lowerLimit': '63.9', 'upperLimit': '140.0'}]}]}, {'title': 'Children < 13 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '32.1', 'comment': 'Not Available due to insufficient number of data points.', 'groupId': 'OG000', 'lowerLimit': '20.2', 'upperLimit': 'NA'}, {'value': '115.9', 'groupId': 'OG001', 'lowerLimit': '45.5', 'upperLimit': '495.0'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Day 40', 'description': 'TTR of all clinical influenza symptoms was defined as the time from treatment initiation to the start of the 24-hour period in which all 7 influenza symptoms had scores \\</= 1 (mild) and remained \\</=1 for at least 21.5 hours. . Reported are TTRs in adults \\>/= 18 years, adults and adolescents \\>/= 13 years and children \\<13 years in the mITTi population.', 'unitOfMeasure': 'hours', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline, and for whom data were available.'}, {'type': 'SECONDARY', 'title': 'Total Symptom Score Area Under the Efficacy Curve (AUE)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '59', 'groupId': 'OG000'}, {'value': '67', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '774.7', 'groupId': 'OG000', 'lowerLimit': '60.8', 'upperLimit': '11435.5'}, {'value': '811.5', 'groupId': 'OG001', 'lowerLimit': '63.0', 'upperLimit': '8648.1'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Day 40', 'description': 'The overall extent and severity of illness was quantified by the AUE of the total symptom scores over the duration of illness, i.e., from the start of treatment to the time symptoms first alleviated. Total symptom scores were calculated from the sum of seven individual symptom scores with each individual symptom scored from 0 (healthy) to 3 (worst sickness) and a maximum total symptom score of 21. The AUE of these average scores was then calculated for each participant using the trapezoidal rule (the trapezoidal rule calculates the area under any curve by adding up all trapezoids under such a curve). A larger area indicates more severe disease. In this study participants were treated for 10 days. If a participant had scored 21 on every visit then AUE would have been 21 score x 10 days x 24 hours/day =5040 score x hours units, which is the highest possible score. The lowest possible score is 0. Reported are results for adults \\>/= 18 years in the mITTi population.', 'unitOfMeasure': 'score * hour', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Time to Resolution of Fever', 'denoms': [{'units': 'Participants', 'counts': [{'value': '38', 'groupId': 'OG000'}, {'value': '35', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': 'Adults >/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.0', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '16.2'}, {'value': '0.5', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '8.8'}]}]}, {'title': 'Adults and adolescents >/= 13 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.0', 'groupId': 'OG000', 'lowerLimit': '0.0', 'upperLimit': '16.2'}, {'value': '0.5', 'groupId': 'OG001', 'lowerLimit': '0.0', 'upperLimit': '8.8'}]}]}, {'title': 'Children < 13 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': 'NA', 'comment': 'Not Available: participant censored for analysis', 'groupId': 'OG000', 'lowerLimit': 'NA', 'upperLimit': 'NA'}, {'value': '26.0', 'comment': 'CI not available for only 2 participants: actual measure values for these participants were 0.0 and 51.9.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Day 40', 'description': 'Fever was defined as temperature \\>/= 37.8 degrees Celsius at any time point during the study. TTR of fever was determined in Adults \\>/= 18 years, Adults and adolescents \\>/= 13 years and Children \\< 13 years of the mITTi population.', 'unitOfMeasure': 'hours', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Viral Load Assessed by Culture', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years, Baseline (BL)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '76', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.38', 'groupId': 'OG000', 'lowerLimit': '0.5', 'upperLimit': '6.0'}, {'value': '3.75', 'groupId': 'OG001', 'lowerLimit': '0.5', 'upperLimit': '6.3'}]}]}, {'title': '>/= 18 years, Change from BL on Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '73', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.50', 'groupId': 'OG000', 'lowerLimit': '-5.3', 'upperLimit': '0.8'}, {'value': '-1.50', 'groupId': 'OG001', 'lowerLimit': '-5.0', 'upperLimit': '1.50'}]}]}, {'title': '>/= 18 years, Change from BL on Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '71', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.50', 'groupId': 'OG000', 'lowerLimit': '-5.5', 'upperLimit': '0.0'}, {'value': '-3.00', 'groupId': 'OG001', 'lowerLimit': '-5.8', 'upperLimit': '1.0'}]}]}, {'title': '>/= 18 years, Change from BL on Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.75', 'groupId': 'OG000', 'lowerLimit': '-5.5', 'upperLimit': '0.0'}, {'value': '-3.25', 'groupId': 'OG001', 'lowerLimit': '-5.8', 'upperLimit': '0.0'}]}]}, {'title': '>/= 18 years, Change from BL on Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '71', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.88', 'groupId': 'OG000', 'lowerLimit': '-5.5', 'upperLimit': '0.0'}, {'value': '-3.25', 'groupId': 'OG001', 'lowerLimit': '-5.8', 'upperLimit': '0.3'}]}]}, {'title': '>/= 18 years, Change from BL on Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '62', 'groupId': 'OG000'}, {'value': '65', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.00', 'groupId': 'OG000', 'lowerLimit': '-5.5', 'upperLimit': '0.3'}, {'value': '-3.25', 'groupId': 'OG001', 'lowerLimit': '-5.8', 'upperLimit': '0.0'}]}]}, {'title': '>/= 18 years, Change from BL on Day 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '65', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.00', 'groupId': 'OG000', 'lowerLimit': '-5.5', 'upperLimit': '0.0'}, {'value': '-3.25', 'groupId': 'OG001', 'lowerLimit': '-5.8', 'upperLimit': '0.0'}]}]}, {'title': '< 18 years, BL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.13', 'groupId': 'OG000', 'lowerLimit': '0.8', 'upperLimit': '6.0'}, {'value': '4.00', 'groupId': 'OG001', 'lowerLimit': '1.8', 'upperLimit': '5.3'}]}]}, {'title': '< 18 years, Change from BL on Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.00', 'groupId': 'OG000', 'lowerLimit': '-2.3', 'upperLimit': '0.8'}, {'value': '-2.00', 'groupId': 'OG001', 'lowerLimit': '-3.3', 'upperLimit': '0.0'}]}]}, {'title': '< 18 years, Change from BL on Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.00', 'groupId': 'OG000', 'lowerLimit': '-3.3', 'upperLimit': '-0.3'}, {'value': '-3.50', 'groupId': 'OG001', 'lowerLimit': '-4.8', 'upperLimit': '-2.3'}]}]}, {'title': '< 18 years, Change from BL on Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.50', 'groupId': 'OG000', 'lowerLimit': '-3.3', 'upperLimit': '-0.3'}, {'value': '-3.50', 'groupId': 'OG001', 'lowerLimit': '-4.8', 'upperLimit': '-1.3'}]}]}, {'title': '< 18 years, Change from BL on Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.50', 'groupId': 'OG000', 'lowerLimit': '-5.3', 'upperLimit': '0.0'}, {'value': '-3.50', 'groupId': 'OG001', 'lowerLimit': '-4.8', 'upperLimit': '-2.3'}]}]}, {'title': '< 18 years, Change from BL on Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.50', 'groupId': 'OG000', 'lowerLimit': '-5.3', 'upperLimit': '1.0'}, {'value': '-3.50', 'groupId': 'OG001', 'lowerLimit': '-4.8', 'upperLimit': '-2.3'}]}]}, {'title': '< 18 years, Change from BL on Day 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.50', 'groupId': 'OG000', 'lowerLimit': '-5.3', 'upperLimit': '0.3'}, {'value': '-3.50', 'groupId': 'OG001', 'lowerLimit': '-4.8', 'upperLimit': '-1.3'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Nasopharyngeal swab samples were cultured in Madin-Darby Canine Kidney cells. Culture supernatants were harvested after 2 weeks, or after a full-blown cytopathic effect was observed. Presence of infectious viruses in the cell culture supernatants (viral titer), expressed as log10 50% Tissue Culture Infectious Dose/milliliter (TCID50/mL), was determined by hemagglutination assay using turkey erythrocytes for H1 and B viruses or by detection of the virus nucleoprotein (NP) using ELISA for H3 viruses. A value of \\< 0.5 log10 TCID50/mL was interpreted as negative. Data are reported for adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'TCID50/mL', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Viral Shedding Assessed by Culture Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years, Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '70', 'groupId': 'OG000'}, {'value': '76', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '91.4', 'groupId': 'OG000'}, {'value': '84.2', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '73', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '67.2', 'groupId': 'OG000'}, {'value': '58.9', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '71', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '15.4', 'groupId': 'OG000'}, {'value': '18.3', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '62', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '3.2', 'groupId': 'OG000'}, {'value': '4.8', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '71', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000'}, {'value': '4.2', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '63', 'groupId': 'OG000'}, {'value': '65', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.9', 'groupId': 'OG000'}, {'value': '1.5', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '65', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '71.4', 'groupId': 'OG000'}, {'value': '75.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '42.9', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Viral shedding was determined through measurement of the viral titer after viral culture in Madin-Darby Canine Kidney cells by hemagglutination assay (for Flu A/H1N1 and Flu B) and NP-ELISA (for Flu A/H3N2) and expressed in log10 TCID50/mL. Reported is the percentage of participants with viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Time to Cessation of Viral Shedding by Cell Culture', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '64', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '105.0', 'groupId': 'OG000', 'lowerLimit': '98.3', 'upperLimit': '109.2'}, {'value': '105.4', 'groupId': 'OG001', 'lowerLimit': '83.0', 'upperLimit': '107.7'}]}]}, {'title': '< 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '150.3', 'groupId': 'OG000', 'lowerLimit': '34.2', 'upperLimit': '891.3'}, {'value': '94.9', 'groupId': 'OG001', 'lowerLimit': '8.6', 'upperLimit': '109.4'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Day 40', 'description': 'Viral shedding was determined through measurement of the viral titer after viral culture in Madin-Darby Canine Kidney cells by hemagglutination assay (for Flu A/H1N1 and Flu B) and NP-ELISA (for Flu A/H3N2) and expressed in log10 TCID50/mL. Reported is the time to cessation of viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'hours', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Viral Load Assessed by Reverse Transcription Polymerase Chain Reaction (RT-PCR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years, Baseline (BL)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '76', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.47', 'groupId': 'OG000', 'lowerLimit': '2.7', 'upperLimit': '8.8'}, {'value': '6.52', 'groupId': 'OG001', 'lowerLimit': '2.8', 'upperLimit': '8.5'}]}]}, {'title': '>/= 18 years, Change from BL on Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '67', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.20', 'groupId': 'OG000', 'lowerLimit': '-6.4', 'upperLimit': '1.6'}, {'value': '-1.35', 'groupId': 'OG001', 'lowerLimit': '-4.6', 'upperLimit': '1.1'}]}]}, {'title': '>/= 18 years, Change from BL on Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '41', 'groupId': 'OG000'}, {'value': '39', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.36', 'groupId': 'OG000', 'lowerLimit': '-8.0', 'upperLimit': '0.1'}, {'value': '-2.34', 'groupId': 'OG001', 'lowerLimit': '-7.7', 'upperLimit': '0.1'}]}]}, {'title': '>/= 18 years, Change from BL on Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '28', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-2.66', 'groupId': 'OG000', 'lowerLimit': '-5.4', 'upperLimit': '-0.3'}, {'value': '-2.62', 'groupId': 'OG001', 'lowerLimit': '-7.8', 'upperLimit': '-0.3'}]}]}, {'title': '>/= 18 years, Change from BL on Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '19', 'groupId': 'OG000'}, {'value': '17', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.51', 'groupId': 'OG000', 'lowerLimit': '-7.3', 'upperLimit': '-2.2'}, {'value': '-2.96', 'groupId': 'OG001', 'lowerLimit': '-4.5', 'upperLimit': '1.3'}]}]}, {'title': '>/= 18 years, Change from BL on Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-3.63', 'groupId': 'OG000', 'lowerLimit': '-8.0', 'upperLimit': '-0.9'}, {'value': '-2.60', 'groupId': 'OG001', 'lowerLimit': '-3.4', 'upperLimit': '0.0'}]}]}, {'title': '>/= 18 years, Change from BL on Day 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-4.80', 'groupId': 'OG000', 'lowerLimit': '-5.4', 'upperLimit': '0.8'}, {'value': '-7.71', 'groupId': 'OG001', 'lowerLimit': '-7.71', 'upperLimit': '-7.71'}]}]}, {'title': '< 18 years, BL', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.88', 'groupId': 'OG000', 'lowerLimit': '2.8', 'upperLimit': '7.7'}, {'value': '5.96', 'groupId': 'OG001', 'lowerLimit': '5.5', 'upperLimit': '7.3'}]}]}, {'title': '< 18 years, Change from BL on Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.66', 'groupId': 'OG000', 'lowerLimit': '-2.7', 'upperLimit': '1.4'}, {'value': '-0.71', 'groupId': 'OG001', 'lowerLimit': '-5.6', 'upperLimit': '0.4'}]}]}, {'title': '< 18 years, Change from BL on Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-1.97', 'groupId': 'OG000', 'lowerLimit': '-2.7', 'upperLimit': '0.3'}, {'value': '-1.73', 'groupId': 'OG001', 'lowerLimit': '-2.7', 'upperLimit': '-1.2'}]}]}, {'title': '< 18 years, Change from BL on Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.56', 'groupId': 'OG000', 'lowerLimit': '1.56', 'upperLimit': '1.56'}, {'value': '-2.26', 'groupId': 'OG001', 'lowerLimit': '-2.9', 'upperLimit': '-1.5'}]}]}, {'title': '< 18 years, Change from BL on Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '-0.89', 'groupId': 'OG000', 'lowerLimit': '-3.2', 'upperLimit': '1.4'}, {'value': '-2.41', 'groupId': 'OG001', 'lowerLimit': '-2.41', 'upperLimit': '-2.41'}]}]}, {'title': '< 18 years, Change from BL on Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.26', 'groupId': 'OG000', 'lowerLimit': '-2.9', 'upperLimit': '1.9'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Nasopharyngeal swab samples were tested for influenza A and B RNA using semi-quantitative RT-PCR specific for influenza A and B matrix gene, respectively, after viral RNA isolation. Cycle threshold (Ct) value was determined for each sample. Conversion of Ct values into viral load, expressed as log10 virus particles/mL (vp/mL), was obtained using external standard curves ran in parallel in all RT-PCR experiments. A value of \\< 2.6 log10 vp/mL for Flu A strains and \\< 3.0 log10 vp/mL for Flu B strains was interpreted as a negative result. Data are reported for adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'log10 vp/mL', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Viral Shedding Assessed by RT-PCR Over Time', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years, Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '97.4', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '69', 'groupId': 'OG000'}, {'value': '75', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '92.8', 'groupId': 'OG000'}, {'value': '88.0', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '73', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '56.7', 'groupId': 'OG000'}, {'value': '49.3', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '65', 'groupId': 'OG000'}, {'value': '64', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '41.5', 'groupId': 'OG000'}, {'value': '23.4', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '67', 'groupId': 'OG000'}, {'value': '73', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '25.4', 'groupId': 'OG000'}, {'value': '21.9', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '67', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '10.6', 'groupId': 'OG000'}, {'value': '9.0', 'groupId': 'OG001'}]}]}, {'title': '>/= 18 years, Day 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '68', 'groupId': 'OG000'}, {'value': '67', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000'}, {'value': '1.5', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}, {'value': '100.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 2/3', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '85.7', 'groupId': 'OG000'}, {'value': '75.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '85.7', 'groupId': 'OG000'}, {'value': '57.1', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '5', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}, {'value': '42.9', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 11', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}, {'value': '14.3', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 15', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '42.9', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years, Day 40', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '0.0', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Viral shedding was determined by direct viral load measurement from nasopharyngeal swabs by RT-PCR assay and expressed in log10 vp/mL. Reported is the percentage of subjects with viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Time to Cessation of Viral Shedding by RT-PCR', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '72', 'groupId': 'OG000'}, {'value': '76', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '178.0', 'groupId': 'OG000', 'lowerLimit': '152.2', 'upperLimit': '227.0'}, {'value': '154.1', 'groupId': 'OG001', 'lowerLimit': '128.5', 'upperLimit': '171.0'}]}]}, {'title': '< 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '181.0', 'groupId': 'OG000', 'lowerLimit': '106.2', 'upperLimit': '943.7'}, {'value': '180.5', 'groupId': 'OG001', 'lowerLimit': '8.6', 'upperLimit': '247.8'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Day 40', 'description': 'Viral shedding was determined by direct viral load measurement from nasopharyngeal swabs by RT-PCR assay and expressed in log10 vp/mL. Reported is the time to cessation of viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'hours', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Persistent Viral Shedding', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.2', 'groupId': 'OG000'}, {'value': '4.7', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline to Day 11 (EOT)', 'description': 'Persistent shedding was defined as a viral load reduction \\<1 log10 vp/mL at end of treatment compared with baseline. Reported is the percentage of participants with persistent viral shedding at end of treatment in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Developed Secondary Illness', 'denoms': [{'units': 'Participants', 'counts': [{'value': '81', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/=18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '73', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.2', 'groupId': 'OG000'}, {'value': '5.1', 'groupId': 'OG001'}]}]}, {'title': '< 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '12.5', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Day 40', 'description': 'Secondary illness included bronchitis, pneumonia, acute sinusitis, sinusitis, lower respiratory infection or otitis media. Reported is the percentage of participants with at least one event in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'mITTi population: all participants randomized to a particular treatment, regardless of whether they received that treatment or not, who received at least one dose of study drug and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Who Initiated Antibiotic Treatment', 'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'OG000'}, {'value': '110', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '98', 'groupId': 'OG000'}, {'value': '101', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '8.2', 'groupId': 'OG000'}, {'value': '5.0', 'groupId': 'OG001'}]}]}, {'title': '< 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Day 40', 'description': 'Secondary illness included bronchitis, pneumonia, acute sinusitis, sinusitis, lower respiratory infection or otitis media. Reported is the percentage of participants with secondary illness, who initiated antibiotic treatment, in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The safety population included all participants who received at least one dose of study drug and had a safety assessment performed post randomization.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Hospitalized', 'denoms': [{'units': 'Participants', 'counts': [{'value': '83', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '6.8', 'groupId': 'OG000'}, {'value': '7.7', 'groupId': 'OG001'}]}]}, {'title': '< 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '11.1', 'groupId': 'OG000'}, {'value': '0.0', 'groupId': 'OG001'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline up to Day 40', 'description': 'Reported is the percentage of participants, who required hospitalization at any time between treatment initiation and the end of the study period, in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITTi population included all participants randomized and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Duration of Hospitalization', 'denoms': [{'units': 'Participants', 'counts': [{'value': '83', 'groupId': 'OG000'}, {'value': '86', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'title': '>/= 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '74', 'groupId': 'OG000'}, {'value': '78', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '7.0', 'groupId': 'OG000', 'lowerLimit': '5.0', 'upperLimit': '14.0'}, {'value': '6.50', 'groupId': 'OG001', 'lowerLimit': '4.0', 'upperLimit': '32.0'}]}]}, {'title': '< 18 years', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}], 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000', 'lowerLimit': '5.0', 'upperLimit': '5.0'}, {'value': 'NA', 'comment': 'N/A=not available as no hospitalization occurred in this arm.', 'groupId': 'OG001', 'lowerLimit': 'NA', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline up to Day 40', 'description': 'Reported is the duration of hospitalization at any time between treatment initiation and the end of the study period, in adults \\>/= 18 years and adolescents and children \\< 18 years.', 'unitOfMeasure': 'days', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED', 'populationDescription': 'The ITTi population included all participants randomized and with central laboratory confirmation of influenza infection, excluding participants infected with oseltamivir-resistant influenza at baseline.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Oseltamivir in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '65.5', 'spread': '26.8', 'groupId': 'OG000'}, {'value': '149', 'spread': '80.7', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Cmax data for adults \\>/= 18 years.', 'unitOfMeasure': 'nanograms per milliliter (ng/mL)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The pharmacokinetic evaluable patient (PKEP) population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Trough Plasma Concentration (Ctrough) of Oseltamivir in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.33', 'spread': '0.641', 'groupId': 'OG000'}, {'value': '6.98', 'spread': '5.1', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Ctrough data for adults \\>/= 18 years.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics : Area Under the Concentration-Time Curve From 0 to 12 Hours (AUC0-12) at Steady State of Oseltamivir in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '197', 'spread': '49.7', 'groupId': 'OG000'}, {'value': '501', 'spread': '320', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose', 'description': 'AUC0-12 was reported at steady state as nanograms per hour per milliliter. (ng\\*hr/mL). Reported here are oseltamivir AUC0-12 data for adults \\>/= 18 years.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Time to Maximum Concentration (Tmax) of Oseltamivir in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.08', 'spread': '0.484', 'groupId': 'OG000'}, {'value': '1.08', 'spread': '0.504', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir tmax data for adults \\>/= 18 years.', 'unitOfMeasure': 'hour', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.15', 'spread': '0.497', 'groupId': 'OG000'}, {'value': '4.79', 'spread': '1.25', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir ke data for adults \\>/= 18 years.', 'unitOfMeasure': '1/hr', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '402', 'spread': '96.0', 'groupId': 'OG000'}, {'value': '367', 'spread': '126', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir CL/F data for adults \\>/= 18 years.', 'unitOfMeasure': 'liter/hour (L/hr)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '77.5', 'spread': '13.6', 'groupId': 'OG000'}, {'value': '75.4', 'spread': '17.5', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Vc/F data for adults \\>/= 18 years.', 'unitOfMeasure': 'liter (L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Cmax of Oseltamivir Carboxylate in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '655', 'spread': '276', 'groupId': 'OG000'}, {'value': '1420', 'spread': '574', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Cmax data for adults \\>/= 18 years.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Ctrough of Oseltamivir Carboxylate in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '363', 'spread': '167', 'groupId': 'OG000'}, {'value': '831', 'spread': '358', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Ctrough data for adults \\>/= 18 years.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics : AUC0-12 at Steady State of Oseltamivir Carboxylate in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '6240', 'spread': '2710', 'groupId': 'OG000'}, {'value': '13800', 'spread': '5670', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate AUC0-12 data for adults \\>/= 18 years.', 'unitOfMeasure': 'ng*hr/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all particiants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Tmax of Oseltamivir Carboxylate in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.83', 'spread': '1.08', 'groupId': 'OG000'}, {'value': '3.96', 'spread': '0.841', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate tmax data for adults \\>/= 18 years.', 'unitOfMeasure': 'hour', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir Carboxylate in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '1.67', 'spread': '0.681', 'groupId': 'OG000'}, {'value': '1.61', 'spread': '0.915', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oxeltamivir carboxylate ke data for adults \\>/= 18 years.', 'unitOfMeasure': '1/hr', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir Carboxylate in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '14.0', 'spread': '5.72', 'groupId': 'OG000'}, {'value': '13.5', 'spread': '7.66', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate CL/F data for adults \\>/= 18 years.', 'unitOfMeasure': 'L/hr', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir Carboxylate in Adults', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}, {'value': '13', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'OG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.39', 'spread': '0.00', 'groupId': 'OG000'}, {'value': '8.39', 'spread': '0.00', 'groupId': 'OG001'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Vc/F data for adults \\>/= 18 years.', 'unitOfMeasure': 'liter (L)', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Cmax of Oseltamivir in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adolescents (\\>/=13 years old) over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '61.9', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '45.9', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '107', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '86.6', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Cmax data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'ng/mL', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Ctrough of Oseltamivir in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.84', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.37', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '6.65', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.88', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Ctrough data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'ng/mL', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: AUC0-12 at Steady State of Oseltamivir in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '229', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '171', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '425', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '339', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose', 'description': 'AUC0-12 will be reported at steady state as ng\\*hr/mL. Reported here are oseltamivir AUC0-12 data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'ng*hr/mL', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all subjects in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Tmax of Oseltamivir in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.25', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'hour', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Cmax of Oseltamivir Carboxylate in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '363', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '848', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '770', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '906', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Cmax data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'ng/mL', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Ctrough of Oseltamivir Carboxylate in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '215', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '459', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '445', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '464', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Ctrough data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'ng/mL', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: AUC0-12 at Steady State of Oseltamivir Carboxylate in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3550', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8010', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '7460', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8420', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose', 'description': 'AUC0-12 will be reported at steady state as ng\\*hr/mL. Reported here are oseltamivir carboxylate AUC0-12 data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'ng*hr/mL', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Tmax of Oseltamivir Carboxylate in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.75', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate tmax data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'hour', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.22', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4.56', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3.40', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5.74', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir ke data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': '1/hr', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '263', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '439', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '212', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '442', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir CL/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'L/hr', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '62.3', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '96.4', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '62.3', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '76.9', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Vc/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'Liter (L)', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir Carboxylate in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.01', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.12', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1.44', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2.12', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate ke data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': '1/hr', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Clearance (CL/F), of Oseltamivir Carboxylate in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '16.9', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '9.36', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '12.1', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '17.8', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate CL/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'L/hr', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}, {'type': 'SECONDARY', 'title': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir Carboxylate in Adolescents and Children', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Adolescents and Children With Pharmacokinetic Evaluation', 'description': 'This analysis set comprises participants \\< 18 years from both arms in the study who underwent pharmacokinetic evaluation. Immunocompromised participants in the Conventional dose arm received oseltamivir syrup at doses ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days. Participants in the Double dose arm received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily over 10 days.'}], 'classes': [{'title': 'Conventional Dose: 60 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.39', 'groupId': 'OG000'}]}]}, {'title': 'Conventional Dose: 75 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.39', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 90 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.39', 'groupId': 'OG000'}]}]}, {'title': 'Double Dose: 150 mg', 'denoms': [{'units': 'Participants', 'counts': [{'value': '1', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.39', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Vc/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.', 'unitOfMeasure': 'Liter (L)', 'reportingStatus': 'POSTED', 'populationDescription': 'The PKEP population comprised all participants in the ITT population who had at least one valid post-dose drug concentration measurement at a scheduled visit time point.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'FG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '105'}, {'groupId': 'FG001', 'numSubjects': '110'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '99'}, {'groupId': 'FG001', 'numSubjects': '100'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '6'}, {'groupId': 'FG001', 'numSubjects': '10'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '3'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}, {'groupId': 'FG001', 'numSubjects': '6'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}]}]}], 'preAssignmentDetails': 'Participant flow is provided for the safety analysis population, which was the primary analysis population for evaluation of safety. Safety population included all participants who received at least one dose of study drug and had a safety assessment performed post randomization. Participants were reported under the actual treatment received.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '105', 'groupId': 'BG000'}, {'value': '110', 'groupId': 'BG001'}, {'value': '215', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Conventional Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.'}, {'id': 'BG001', 'title': 'Double Dose', 'description': 'Immunocompromised participants received oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '43.0', 'spread': '15.5', 'groupId': 'BG000'}, {'value': '43.9', 'spread': '16.5', 'groupId': 'BG001'}, {'value': '43.5', 'spread': '16.0', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '57', 'groupId': 'BG000'}, {'value': '62', 'groupId': 'BG001'}, {'value': '119', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '48', 'groupId': 'BG000'}, {'value': '48', 'groupId': 'BG001'}, {'value': '96', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '21', 'groupId': 'BG001'}, {'value': '36', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '90', 'groupId': 'BG000'}, {'value': '89', 'groupId': 'BG001'}, {'value': '179', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '3', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '27', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '60', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '72', 'groupId': 'BG000'}, {'value': '72', 'groupId': 'BG001'}, {'value': '144', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '2', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2014-06-18', 'size': 5731411, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2018-04-24T11:24', 'hasProtocol': True}, {'date': '2017-08-04', 'size': 1513818, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2018-04-24T11:24', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 228}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-02-04', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-06', 'completionDateStruct': {'date': '2017-05-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-06-15', 'studyFirstSubmitDate': '2007-10-16', 'resultsFirstSubmitDate': '2018-04-24', 'studyFirstSubmitQcDate': '2007-10-16', 'lastUpdatePostDateStruct': {'date': '2018-07-12', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2018-06-15', 'studyFirstPostDateStruct': {'date': '2007-10-17', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2018-07-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-05-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants With Adverse Events', 'timeFrame': 'Baseline up to Day 40', 'description': 'An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.'}, {'measure': 'Percentage of Participants Who Developed Viral Resistance to Oseltamivir', 'timeFrame': 'Baseline up to Day 40', 'description': 'Resistance was defined as the presence of oseltamivir resistance mutations in viruses isolated from nasopharyngeal swab samples, identified by sequencing of the neuraminidase (NA) and hemagglutinin (HA) genes (genotypic resistance) and/or determination of the oseltamivir concentration at which the response is reduced by half (IC50) in an NA inhibition assay (phenotypic resistance). Reported are post-baseline phenotypic and genotypic resistance in adults \\>/= 18 years and children and adolescents \\<18 years in the modified Intent-to-Treat infected (mITTi) population.'}, {'measure': 'Percentage of Participants With Tissue Rejection or Graft Versus Host Disease (GVHD)', 'timeFrame': 'Baseline up to Day 40', 'description': 'The percentage of transplant patients in the safety population who experienced tissue rejection and/or GvHD is reported.'}], 'secondaryOutcomes': [{'measure': 'Time to Resolution (TTR) of All Clinical Influenza Symptoms', 'timeFrame': 'Baseline up to Day 40', 'description': 'TTR of all clinical influenza symptoms was defined as the time from treatment initiation to the start of the 24-hour period in which all 7 influenza symptoms had scores \\</= 1 (mild) and remained \\</=1 for at least 21.5 hours. . Reported are TTRs in adults \\>/= 18 years, adults and adolescents \\>/= 13 years and children \\<13 years in the mITTi population.'}, {'measure': 'Total Symptom Score Area Under the Efficacy Curve (AUE)', 'timeFrame': 'Baseline up to Day 40', 'description': 'The overall extent and severity of illness was quantified by the AUE of the total symptom scores over the duration of illness, i.e., from the start of treatment to the time symptoms first alleviated. Total symptom scores were calculated from the sum of seven individual symptom scores with each individual symptom scored from 0 (healthy) to 3 (worst sickness) and a maximum total symptom score of 21. The AUE of these average scores was then calculated for each participant using the trapezoidal rule (the trapezoidal rule calculates the area under any curve by adding up all trapezoids under such a curve). A larger area indicates more severe disease. In this study participants were treated for 10 days. If a participant had scored 21 on every visit then AUE would have been 21 score x 10 days x 24 hours/day =5040 score x hours units, which is the highest possible score. The lowest possible score is 0. Reported are results for adults \\>/= 18 years in the mITTi population.'}, {'measure': 'Time to Resolution of Fever', 'timeFrame': 'Baseline up to Day 40', 'description': 'Fever was defined as temperature \\>/= 37.8 degrees Celsius at any time point during the study. TTR of fever was determined in Adults \\>/= 18 years, Adults and adolescents \\>/= 13 years and Children \\< 13 years of the mITTi population.'}, {'measure': 'Change From Baseline in Viral Load Assessed by Culture', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Nasopharyngeal swab samples were cultured in Madin-Darby Canine Kidney cells. Culture supernatants were harvested after 2 weeks, or after a full-blown cytopathic effect was observed. Presence of infectious viruses in the cell culture supernatants (viral titer), expressed as log10 50% Tissue Culture Infectious Dose/milliliter (TCID50/mL), was determined by hemagglutination assay using turkey erythrocytes for H1 and B viruses or by detection of the virus nucleoprotein (NP) using ELISA for H3 viruses. A value of \\< 0.5 log10 TCID50/mL was interpreted as negative. Data are reported for adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Percentage of Participants With Viral Shedding Assessed by Culture Over Time', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Viral shedding was determined through measurement of the viral titer after viral culture in Madin-Darby Canine Kidney cells by hemagglutination assay (for Flu A/H1N1 and Flu B) and NP-ELISA (for Flu A/H3N2) and expressed in log10 TCID50/mL. Reported is the percentage of participants with viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Time to Cessation of Viral Shedding by Cell Culture', 'timeFrame': 'Baseline up to Day 40', 'description': 'Viral shedding was determined through measurement of the viral titer after viral culture in Madin-Darby Canine Kidney cells by hemagglutination assay (for Flu A/H1N1 and Flu B) and NP-ELISA (for Flu A/H3N2) and expressed in log10 TCID50/mL. Reported is the time to cessation of viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Change From Baseline in Viral Load Assessed by Reverse Transcription Polymerase Chain Reaction (RT-PCR)', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Nasopharyngeal swab samples were tested for influenza A and B RNA using semi-quantitative RT-PCR specific for influenza A and B matrix gene, respectively, after viral RNA isolation. Cycle threshold (Ct) value was determined for each sample. Conversion of Ct values into viral load, expressed as log10 virus particles/mL (vp/mL), was obtained using external standard curves ran in parallel in all RT-PCR experiments. A value of \\< 2.6 log10 vp/mL for Flu A strains and \\< 3.0 log10 vp/mL for Flu B strains was interpreted as a negative result. Data are reported for adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Percentage of Participants With Viral Shedding Assessed by RT-PCR Over Time', 'timeFrame': 'Baseline (Day 1), Day 2/3, Day 6, Day 8, Day 11 end of treatment (EOT), follow-up (FU) Day 15 and FU Day 40.', 'description': 'Viral shedding was determined by direct viral load measurement from nasopharyngeal swabs by RT-PCR assay and expressed in log10 vp/mL. Reported is the percentage of subjects with viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Time to Cessation of Viral Shedding by RT-PCR', 'timeFrame': 'Baseline up to Day 40', 'description': 'Viral shedding was determined by direct viral load measurement from nasopharyngeal swabs by RT-PCR assay and expressed in log10 vp/mL. Reported is the time to cessation of viral shedding over time in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Percentage of Participants With Persistent Viral Shedding', 'timeFrame': 'Baseline to Day 11 (EOT)', 'description': 'Persistent shedding was defined as a viral load reduction \\<1 log10 vp/mL at end of treatment compared with baseline. Reported is the percentage of participants with persistent viral shedding at end of treatment in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Percentage of Participants Who Developed Secondary Illness', 'timeFrame': 'Baseline up to Day 40', 'description': 'Secondary illness included bronchitis, pneumonia, acute sinusitis, sinusitis, lower respiratory infection or otitis media. Reported is the percentage of participants with at least one event in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Percentage of Participants Who Initiated Antibiotic Treatment', 'timeFrame': 'Baseline up to Day 40', 'description': 'Secondary illness included bronchitis, pneumonia, acute sinusitis, sinusitis, lower respiratory infection or otitis media. Reported is the percentage of participants with secondary illness, who initiated antibiotic treatment, in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Percentage of Participants Hospitalized', 'timeFrame': 'Baseline up to Day 40', 'description': 'Reported is the percentage of participants, who required hospitalization at any time between treatment initiation and the end of the study period, in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Duration of Hospitalization', 'timeFrame': 'Baseline up to Day 40', 'description': 'Reported is the duration of hospitalization at any time between treatment initiation and the end of the study period, in adults \\>/= 18 years and adolescents and children \\< 18 years.'}, {'measure': 'Pharmacokinetics: Maximum Plasma Concentration (Cmax) of Oseltamivir in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Cmax data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Trough Plasma Concentration (Ctrough) of Oseltamivir in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Ctrough data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics : Area Under the Concentration-Time Curve From 0 to 12 Hours (AUC0-12) at Steady State of Oseltamivir in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose', 'description': 'AUC0-12 was reported at steady state as nanograms per hour per milliliter. (ng\\*hr/mL). Reported here are oseltamivir AUC0-12 data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Time to Maximum Concentration (Tmax) of Oseltamivir in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir tmax data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir ke data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir CL/F data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Vc/F data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Cmax of Oseltamivir Carboxylate in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Cmax data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Ctrough of Oseltamivir Carboxylate in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Ctrough data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics : AUC0-12 at Steady State of Oseltamivir Carboxylate in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate AUC0-12 data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Tmax of Oseltamivir Carboxylate in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate tmax data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir Carboxylate in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oxeltamivir carboxylate ke data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir Carboxylate in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate CL/F data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir Carboxylate in Adults', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Vc/F data for adults \\>/= 18 years.'}, {'measure': 'Pharmacokinetics: Cmax of Oseltamivir in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Cmax data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Ctrough of Oseltamivir in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Ctrough data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: AUC0-12 at Steady State of Oseltamivir in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose', 'description': 'AUC0-12 will be reported at steady state as ng\\*hr/mL. Reported here are oseltamivir AUC0-12 data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Tmax of Oseltamivir in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Cmax of Oseltamivir Carboxylate in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Cmax data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Ctrough of Oseltamivir Carboxylate in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Ctrough data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: AUC0-12 at Steady State of Oseltamivir Carboxylate in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours on Day 6 or any day after the 11th dose', 'description': 'AUC0-12 will be reported at steady state as ng\\*hr/mL. Reported here are oseltamivir carboxylate AUC0-12 data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Tmax of Oseltamivir Carboxylate in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate tmax data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir ke data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Apparent Clearance (CL/F) of Oseltamivir in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir CL/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir Vc/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Elimination Constant (ke) of Oseltamivir Carboxylate in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate ke data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Apparent Clearance (CL/F), of Oseltamivir Carboxylate in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate CL/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}, {'measure': 'Pharmacokinetics: Apparent Volume of Distribution (Vc/F) of Oseltamivir Carboxylate in Adolescents and Children', 'timeFrame': 'Pre-dose (30 minutes), 1.5, 4, 8 hours postdose on Day 6 or any day after the 11th dose', 'description': 'Reported here are oseltamivir carboxylate Vc/F data for adolescents and children \\< 18 years. Individual data are provided as participants received different drug doses. Drug dose is indicated in the row title for each participant.'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Influenza, Human']}, 'referencesModule': {'references': [{'pmid': '31667696', 'type': 'DERIVED', 'citation': 'Mitha E, Krivan G, Jacobs F, Nagler A, Alrabaa S, Mykietiuk A, Kenwright A, Le Pogam S, Clinch B, Vareikiene L. Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients. Infect Dis Ther. 2019 Dec;8(4):613-626. doi: 10.1007/s40121-019-00271-8. Epub 2019 Oct 30.'}]}, 'descriptionModule': {'briefSummary': 'This 2-arm study will investigate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised participants and characterize the effects of oseltamivir in immunocompromised participants on the development of resistant influenza virus. Eligible immunocompromised participants with laboratory-confirmed influenza will be randomized to receive either conventional dose (30 milligrams \\[mg\\] to 75 mg twice daily orally \\[po\\], depending on age and weight) or double dose (60 mg-150 mg twice daily po depending on age and weight) olseltamivir for 10 days. Nasal and throat swabs will be taken, and safety evaluations made, at intervals during the study. The anticipated time on study medication is 10 days and the anticipated time on study is 40 days.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '1 Year', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Rapid diagnostic test, PCR, or viral culture positive for influenza in the 96 hours prior to first dose\n* Immunocompromised participants with primary or secondary immunodeficiency\n* Symptoms suggestive of influenza-like illness\n* Use of an effective contraceptive, as specified by protocol; women of childbearing potential cannot be pregnant or breastfeeding\n\nExclusion Criteria:\n\n* Influenza vaccination with live attenuated vaccine in the 2 weeks prior to randomization\n* Antiviral treatment for influenza in 2 weeks prior to randomization\n* Severe hepatic impairment\n* Any current renal replacement therapy\n* Any gastrointestinal disorders which may interfere with the absorption of oseltamivir\n* Participation in a study with an investigational drug from 4 weeks prior to study start until study end'}, 'identificationModule': {'nctId': 'NCT00545532', 'briefTitle': 'A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.', 'organization': {'class': 'INDUSTRY', 'fullName': 'Hoffmann-La Roche'}, 'officialTitle': 'A Double-Blind, Randomized, Stratified Multi-Center Trial Evaluating Conventional and Double Dose Oseltamivir in the Treatment of Immunocompromised Patients With Influenza', 'orgStudyIdInfo': {'id': 'NV20234'}, 'secondaryIdInfos': [{'id': '2006-002468-24', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Conventional dose', 'description': 'Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 30 to 75 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 75 mg twice daily for adults/adolescents greater than or equal to (\\>/=) 13 years old or placebo-matched to oseltamivir twice daily over 10 days.', 'interventionNames': ['Drug: oseltamivir', 'Other: placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Double dose', 'description': 'Immunocompromised participants will receive oseltamivir syrup at a dose ranging from 60 to 150 mg based on body weight, twice daily for children (1 to 12 years old) and oseltamivir capsules 150 mg twice daily for adults/adolescents (\\>/=13 years old) or placebo matched to oseltamivir twice daily over 10 days.', 'interventionNames': ['Drug: oseltamivir', 'Other: placebo']}], 'interventions': [{'name': 'oseltamivir', 'type': 'DRUG', 'otherNames': ['Tamiflu'], 'description': "Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participant's age and weight) po twice daily for 10 days", 'armGroupLabels': ['Conventional dose', 'Double dose']}, {'name': 'placebo', 'type': 'OTHER', 'description': 'Placebo matched to oseltamivir po twice daily for 10 days', 'armGroupLabels': ['Conventional dose', 'Double dose']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Uni of Alabama At Birmingham; Division of Nephrology', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '35233', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'University of Alabama at Birmingham; Pediatric Nephrology', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '90211', 'city': 'Beverly Hills', 'state': 'California', 'country': 'United States', 'facility': 'Pacific Oaks Medical Group', 'geoPoint': {'lat': 34.07362, 'lon': -118.40036}}, {'zip': '91505', 'city': 'Burbank', 'state': 'California', 'country': 'United States', 'facility': 'Providence Clinical Research', 'geoPoint': {'lat': 34.18084, 'lon': -118.30897}}, {'zip': '90015', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'AIDS Research Alliance', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90095', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'UCLA Medical center Medicine/Nephrology', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '95817', 'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'University of California Davis Health System', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'zip': '94115', 'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'facility': 'CALIFORNIA PACIFIC MEDICAL CENTER; Office of Dr. Venkat Peddi', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'zip': '80045', 'city': 'Aurora', 'state': 'Colorado', 'country': 'United States', 'facility': 'University of Colorado; Kidney Transplant Center Office of Dr. Laurence Chan', 'geoPoint': {'lat': 39.72943, 'lon': -104.83192}}, {'zip': '06611', 'city': 'Trumbull', 'state': 'Connecticut', 'country': 'United States', 'facility': 'New England Research Associates', 'geoPoint': {'lat': 41.24287, 'lon': -73.20067}}, {'zip': '19713', 'city': 'Newark', 'state': 'Delaware', 'country': 'United States', 'facility': 'Christiana Care Health System', 'geoPoint': {'lat': 39.68372, 'lon': -75.74966}}, {'zip': '32810', 'city': 'Orlando', 'state': 'Florida', 'country': 'United States', 'facility': 'Omega Research Consultants', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '33143', 'city': 'South Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Kendall South Medical Center Inc.', 'geoPoint': {'lat': 25.7076, 'lon': -80.29338}}, {'zip': '33701', 'city': 'St. Petersburg', 'state': 'Florida', 'country': 'United States', 'facility': "All Children'S Hospital; Pediatric Blood & Marrow Transplant Program", 'geoPoint': {'lat': 27.77086, 'lon': -82.67927}}, {'zip': '33319', 'city': 'Tamarac', 'state': 'Florida', 'country': 'United States', 'facility': 'Vita Research Solutions, Inc', 'geoPoint': {'lat': 26.21286, 'lon': -80.24977}}, {'zip': '33612', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'University of South Florida', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30309', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Piedmont Hospital; Transplant Services', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30322', 'city': 'Atlanta', 'state': 'Georgia', 'country': 'United States', 'facility': 'EMORY UNIVERSITY; Bone Marrow & Stem Cell Transplant Center', 'geoPoint': {'lat': 33.749, 'lon': -84.38798}}, {'zip': '30912', 'city': 'Augusta', 'state': 'Georgia', 'country': 'United States', 'facility': 'Medical College of Georgia; Medicine/ Nephrology', 'geoPoint': {'lat': 33.47097, 'lon': -81.97484}}, {'zip': '60611', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Northwestern Memorial Hospital; Divison of Infectious Diseases/ Dept of Medicine', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush Uni Medical Center; Medicine/ Section of Infectious Diseases', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '60655', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'University of Chicago; Infectious Disease', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '70112', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Tulane University Medical Center', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '21201', 'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'facility': 'University of Maryland School of Medicine', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'zip': '02115', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': "Brigham & Women'S Hospital", 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '01107', 'city': 'Springfield', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Western New England Renal & Transplant Associates, P.C.', 'geoPoint': {'lat': 42.10148, 'lon': -72.58981}}, {'zip': '48109-0378', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'Uni of Michigan Medical Center; Internal Medicine/ Infectious Disease', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '48201', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Karmanos Cancer Inst. ; Hudson Webber; Cancer Research Building', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '48202-2689', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Henry Ford Health System; Gastroenterology', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '48210', 'city': 'Detroit', 'state': 'Michigan', 'country': 'United States', 'facility': 'Wayne State University School of Medicine', 'geoPoint': {'lat': 42.33143, 'lon': -83.04575}}, {'zip': '48917', 'city': 'Lansing', 'state': 'Michigan', 'country': 'United States', 'facility': 'Beals Institute PC', 'geoPoint': {'lat': 42.73253, 'lon': -84.55553}}, {'zip': '63110', 'city': 'St Louis', 'state': 'Missouri', 'country': 'United States', 'facility': 'Washington University; Wash Uni. Sch. Of Med', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '08103', 'city': 'Camden', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Our Lady of Lourdes Medical Center; Transplant Dept', 'geoPoint': {'lat': 39.92595, 'lon': -75.11962}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'country': 'United States', 'facility': 'Hackensack University Medical Center', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '11042', 'city': 'New Hyde Park', 'state': 'New York', 'country': 'United States', 'facility': 'Long Island Jewish/North Shore Hospital', 'geoPoint': {'lat': 40.7351, 'lon': -73.68791}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Mount Sinai Medical Center; Division of Liver Diseases', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '28210', 'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'facility': 'DJL Clinical Research PLLC', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '28105', 'city': 'Matthews', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Novant Health Pulmonary and Critical Care', 'geoPoint': {'lat': 35.11681, 'lon': -80.72368}}, {'zip': '27609', 'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Duke University Health Systems', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'zip': '27157', 'city': 'Winston-Salem', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wake Forest University Baptist Medical Center', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '45267', 'city': 'Cincinnati', 'state': 'Ohio', 'country': 'United States', 'facility': 'Uni of Cincinnati Medical Center; Nephrology & Hypertension', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cleveland Clinic Foundation; Infectious Disease', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '43606', 'city': 'Toledo', 'state': 'Ohio', 'country': 'United States', 'facility': 'Toledo Hospital', 'geoPoint': {'lat': 41.66394, 'lon': -83.55521}}, {'zip': '73112-4481', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Nazih Zuhdi Transplant Inst. ; Integris Baptist Medical Center', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '17033', 'city': 'Hershey', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Penn State Milton S. Hershey Medical Center', 'geoPoint': {'lat': 40.28592, 'lon': -76.65025}}, {'zip': '19102', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Drexel University; College of Medicine', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Uni of Pennsylvania; Infectious Diseases', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '19104', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'University of Pennsylvania Health System', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '15213', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': "Children'S Hospital of Pittsburgh; Infectious Disease", 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '29425', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Medical University of South Carolina; Pediatric Cardiology', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '75235', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': "Children'S Medical Center of Dallas", 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75246', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Baylor University Medical Center Transplant Administration', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'UT Southwestern Medical Center; Pediatrics Dept.', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': 'TX 75246', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Sammons Cancer Center-Baylor University; Blood & Marrow Transplantation', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77005', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'The Methodist Hospital', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'M.D Anderson Cancer Center; Infectious Diseases, Infection Control, and Employee Health', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '79430', 'city': 'Lubbock', 'state': 'Texas', 'country': 'United States', 'facility': 'Texas Tech University Health Sciences Center; Department of Urology', 'geoPoint': {'lat': 33.57786, 'lon': -101.85517}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas Health Science Center Transplant center', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '76508', 'city': 'Temple', 'state': 'Texas', 'country': 'United States', 'facility': 'Scott and White Division of Nephrology Dept of Medicine', 'geoPoint': {'lat': 31.09823, 'lon': -97.34278}}, {'zip': '84132', 'city': 'Salt Lake City', 'state': 'Utah', 'country': 'United States', 'facility': 'University of Utah Health Science Center Gastroenterology', 'geoPoint': {'lat': 40.76078, 'lon': -111.89105}}, {'zip': '1202', 'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Hospital General de Agudos Juan Antonio Fernandez; infectología', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'city': 'Buenos Aires', 'country': 'Argentina', 'facility': 'Instituto Medico Platense', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '1426', 'city': 'Ciudad Autonoma Buenos Aires', 'country': 'Argentina', 'facility': 'Instituto Medico Especializado Alexander Fleming'}, {'zip': '1430', 'city': 'Ciudad Autonoma Buenos Aires', 'country': 'Argentina', 'facility': 'Hospital General de Agudos Dr. Ignacio Pirovano'}, {'zip': '1725', 'city': 'La Plata', 'country': 'Argentina', 'facility': 'Hospital Italiano de La Plata', 'geoPoint': {'lat': -34.92126, 'lon': -57.95442}}, {'zip': 'S3000CII', 'city': 'Santa Fe', 'country': 'Argentina', 'facility': 'Hospital de Niños Dr. Orlando Alassia', 'geoPoint': {'lat': -31.64881, 'lon': -60.70868}}, {'zip': '9300', 'city': 'Aalst', 'country': 'Belgium', 'facility': 'Onze Lieve Vrouwziekenhuis Aalst', 'geoPoint': {'lat': 50.93604, 'lon': 4.0355}}, {'zip': '1000', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Institut Jules Bordet', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '1070', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'Hospital Erasme; Neurologie', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '1090', 'city': 'Brussels', 'country': 'Belgium', 'facility': 'UZ Brussel', 'geoPoint': {'lat': 50.85045, 'lon': 4.34878}}, {'zip': '21040-360', 'city': 'Rio de Janeiro', 'state': 'Rio de Janeiro', 'country': 'Brazil', 'facility': 'Fiocruz - Fundação Oswaldo Cruz', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '01323-020', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital Alemao Oswaldo Cruz; Oncologia', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '04023-062', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Iop - Graacc - Unifesp', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '04038-002', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '05403-000', 'city': 'São Paulo', 'state': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital das Clinicas - FMUSP', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'UMHA - Sv. Georgi; Clinic of Nephrology & Haemodialysis', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': 'UMHAT Sv. Georgi, EAD; Clinic of Infectious Diseases', 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '1431', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Mhat Alexandrovska Ead ; Clinic of Nephrology & Transplantation, Uni Hospital', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '1527', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': 'Specialized Hospital for children with oncohaematologica Diseases; Dept. Of Transplantations', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': 'R3E 6518', 'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'facility': 'Uni of Manitoba; Faculty of Medicine', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'S7M 0Z9', 'city': 'Saskatoon', 'state': 'Saskatchewan', 'country': 'Canada', 'facility': "St Paul'S", 'geoPoint': {'lat': 52.13238, 'lon': -106.66892}}, {'zip': '7500539', 'city': 'Santiago', 'country': 'Chile', 'facility': 'Hospital Luis Calvo Mackenna; Unidad de Investigacion', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8207257', 'city': 'Santiago', 'country': 'Chile', 'facility': 'Hospital Dr. Sotero del Rio', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '2520000', 'city': 'Viña Del Mar Valparaiso', 'country': 'Chile', 'facility': 'Centro de Investigaciones Clinicas Viña del Mar'}, {'city': 'Barranquilla', 'country': 'Colombia', 'facility': 'Infectologos Asociados', 'geoPoint': {'lat': 10.96854, 'lon': -74.78132}}, {'city': 'Bogotá', 'country': 'Colombia', 'facility': 'Simedics Ips', 'geoPoint': {'lat': 4.60971, 'lon': -74.08175}}, {'city': 'Cali', 'country': 'Colombia', 'facility': 'Centro de Investigaciones Clinicas S.A.S', 'geoPoint': {'lat': 3.43054, 'lon': -76.5199}}, {'city': 'Floridablanca', 'country': 'Colombia', 'facility': 'Fundacion Cardiovascular de Colombia - Instituto del Corazón', 'geoPoint': {'lat': 7.06222, 'lon': -73.08644}}, {'zip': '625 00', 'city': 'Brno', 'country': 'Czechia', 'facility': 'Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika', 'geoPoint': {'lat': 49.19522, 'lon': 16.60796}}, {'zip': '300 00', 'city': 'Pilsen', 'country': 'Czechia', 'facility': 'Fakultni Nemocnice; Hemato-Oncology', 'geoPoint': {'lat': 49.74747, 'lon': 13.37759}}, {'zip': '12820', 'city': 'Prague', 'country': 'Czechia', 'facility': 'The Institute of Hematology and Blood Transfusion Transplantation Unit; Hematology and Blood Transf', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '150 06', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Fakultni nemocnice v Motole; Klinika detske hematologie a onkologie UK 2.LF', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '390 01', 'city': 'Tábor', 'country': 'Czechia', 'facility': 'KASMED, s.r.o.; Alergologie a klinicka imunologie', 'geoPoint': {'lat': 49.41441, 'lon': 14.6578}}, {'zip': '411 55', 'city': 'Terezín', 'country': 'Czechia', 'facility': 'Revmatologicka Ambulance-Terezin', 'geoPoint': {'lat': 50.511, 'lon': 14.15055}}, {'zip': '760 01', 'city': 'Zlín', 'country': 'Czechia', 'facility': 'Revmatologicka ambulance', 'geoPoint': {'lat': 49.22645, 'lon': 17.67065}}, {'zip': '10617', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'West Tallinn Central Hospital; Nephrology', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '13419', 'city': 'Tallinn', 'country': 'Estonia', 'facility': 'North Estonia medical Centre; Hematology', 'geoPoint': {'lat': 59.43696, 'lon': 24.75353}}, {'zip': '51014', 'city': 'Tartu', 'country': 'Estonia', 'facility': 'Tartu Uni Clinics; Clinic of Surgery & Internal Medicine Dept of Nephrology', 'geoPoint': {'lat': 58.38062, 'lon': 26.72509}}, {'zip': '51014', 'city': 'Tartu', 'country': 'Estonia', 'facility': 'Tartu Uni Hospital; Hematology - Oncology Clinic', 'geoPoint': {'lat': 58.38062, 'lon': 26.72509}}, {'zip': '51014', 'city': 'Tartu', 'country': 'Estonia', 'facility': 'Tartu University Hospital; Department of Infectious Diseases', 'geoPoint': {'lat': 58.38062, 'lon': 26.72509}}, {'zip': '69317', 'city': 'Lyon', 'country': 'France', 'facility': 'Centre Hospitalier de la Croix Rousse', 'geoPoint': {'lat': 45.74906, 'lon': 4.84789}}, {'zip': '75019', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Robert Debre; Pediatric Hematology Dept', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75475', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Saint Louis; Service de Nephrologie - Transplantation', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75908', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Europeen Georges Pompidou; Service de Nephrologie', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '31059', 'city': 'Toulouse', 'country': 'France', 'facility': 'Hopital Rangueil; Nephrologie', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}, {'zip': '37044', 'city': 'Tours', 'country': 'France', 'facility': 'CHRU Bretonneau', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}, {'zip': '52057', 'city': 'Aachen', 'country': 'Germany', 'facility': 'Uniklinik RWTH Aachen; Med. Klinik II; Klinik für Nephrologie und klinische Immunologie', 'geoPoint': {'lat': 50.77664, 'lon': 6.08342}}, {'zip': '13353', 'city': 'Berlin', 'country': 'Germany', 'facility': 'Charite - Campus Virchow Klinikum; Abteilung fuer Chirurgie', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '45122', 'city': 'Essen', 'country': 'Germany', 'facility': 'Universitätsklinikum Essen; Innere Klinik und Poliklinik für Tumorforschung', 'geoPoint': {'lat': 51.45657, 'lon': 7.01228}}, {'zip': '20246', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Universitätsklinikum Hamburg-Eppendorf', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '69120', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'UNI-Klinikum Heidelberg Chirurgische Klinik', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '80336', 'city': 'München', 'country': 'Germany', 'facility': 'Ludwig-Maximilian-Universitaetsklinik; Med. Poliklinik/Infektiologie', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': '80336', 'city': 'München', 'country': 'Germany', 'facility': 'Ludwig-Maximilians-Universitaet; Medizinische Klinik und Poliklinik IV', 'geoPoint': {'lat': 51.60698, 'lon': 13.31243}}, {'zip': '48149', 'city': 'Münster', 'country': 'Germany', 'facility': 'Universitaetsklinikum Muenster; Paedriatrische Haematologie und Onkologie', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '01001', 'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'Clinica Familiar Luis Angel Garcia', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'zip': '01009', 'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'CERICAP', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'zip': '1015', 'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'Centro de Investigaciones Pediatricas', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'Hospital Roosevelt Guatemala; Clinica de Infecciosas', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'city': 'Guatemala City', 'country': 'Guatemala', 'facility': 'Unidad Nacional de Oncologia Pediatrica', 'geoPoint': {'lat': 14.64072, 'lon': -90.51327}}, {'zip': '1096', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Fov.Onk.Egyesitett Szt. Istvan es Szt Laszlo Korh.-Rend.Int.', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '4032', 'city': 'Debrecen', 'country': 'Hungary', 'facility': 'Debreceni Egyetem, Orvos- és Egészségtudományi Centrum;', 'geoPoint': {'lat': 47.53167, 'lon': 21.62444}}, {'zip': '9024', 'city': 'Győr', 'country': 'Hungary', 'facility': 'Petz Aladar Megyei Korhaz; Hematologia', 'geoPoint': {'lat': 47.68333, 'lon': 17.63512}}, {'zip': '5700', 'city': 'Gyula', 'country': 'Hungary', 'facility': 'Bekes Megyei Kepviselotestulet Pandy Kalman Korhaza', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}}, {'zip': '5703', 'city': 'Gyula', 'country': 'Hungary', 'facility': 'Békés Megyei Pándy Kálmán Kórház; Onkologiai tanszek', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}}, {'zip': '7624', 'city': 'Pécs', 'country': 'Hungary', 'facility': 'Pecsi Tudomanyegyetem', 'geoPoint': {'lat': 46.07617, 'lon': 18.22814}}, {'zip': '6720', 'city': 'Szeged', 'country': 'Hungary', 'facility': 'University of Szeged; Transplantation Department', 'geoPoint': {'lat': 46.253, 'lon': 20.14824}}, {'zip': '8000', 'city': 'Székesfehérvár', 'country': 'Hungary', 'facility': 'Fejer Megyei Szent Gyorgy Korhaz', 'geoPoint': {'lat': 47.18995, 'lon': 18.41034}}, {'zip': '5000', 'city': 'Szolnok', 'country': 'Hungary', 'facility': 'Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.', 'geoPoint': {'lat': 47.18066, 'lon': 20.19835}}, {'zip': '8200', 'city': 'Veszprém', 'country': 'Hungary', 'facility': 'Veszprem Megyei Csolnoky Ferenc Korhaz Nonprofit Zrt.', 'geoPoint': {'lat': 47.09327, 'lon': 17.91149}}, {'zip': '31096', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam Health Care Campus; Hematology', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'zip': '91120', 'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah University Hospital - Ein Kerem; BMT & Cancer Immunotherapy Dept.', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin MC- Belinson campus', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center-Golda Campus - Hasharon; Department of Transplantation', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'Rabin Medical Center; Liver Inst.', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}, {'zip': '52662', 'city': 'Ramat Gan', 'country': 'Israel', 'facility': 'Chaim Sheba Medical Center; Hematology BMT & CBB', 'geoPoint': {'lat': 32.08227, 'lon': 34.81065}}, {'zip': '64239', 'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Sourasky MC; Transplant Unit', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}, {'zip': '52621', 'city': 'Tel Litwinsky', 'country': 'Israel', 'facility': 'Chaim Sheba MC; Pediatric Hematology Oncology', 'geoPoint': {'lat': 32.05096, 'lon': 34.84588}}, {'zip': '43100', 'city': 'Parma', 'state': 'Emilia-Romagna', 'country': 'Italy', 'facility': 'Azienda Ospedaliera; Divisione Malattie Infettive E Tropicali', 'geoPoint': {'lat': 44.79935, 'lon': 10.32618}}, {'zip': '00168', 'city': 'Rome', 'state': 'Lazio', 'country': 'Italy', 'facility': "POLICLINICO Universitatio A.Gemelli, Div. Chirurgia Generale e Trapianti d'Organo", 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': 'RM 00149', 'city': 'Rome', 'state': 'Lazio', 'country': 'Italy', 'facility': 'I.N.M.I. L. Spallanzani IRCCS', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'zip': '25126', 'city': 'Brescia', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'ASST DEGLI SPEDALI CIVILI DI BRESCIA; Dipartimento Malattie Infettive', 'geoPoint': {'lat': 45.53558, 'lon': 10.21472}}, {'zip': '20052', 'city': 'Monza', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'ASST DI MONZA; Divisione Malattie Infettive', 'geoPoint': {'lat': 45.58005, 'lon': 9.27246}}, {'zip': '27100', 'city': 'Pavia', 'state': 'Lombardy', 'country': 'Italy', 'facility': 'Fondazione IRCCS Policlinico San Matteo', 'geoPoint': {'lat': 45.19205, 'lon': 9.15917}}, {'zip': '20122', 'city': 'Milano', 'state': 'Molise', 'country': 'Italy', 'facility': "Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico; Clinica Pediatica De Macchi"}, {'zip': 'LV-1002', 'city': 'Riga', 'country': 'Latvia', 'facility': 'Latvia Transplantation Center P. Stradina Hospital; Transplantation', 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': 'LV-1004', 'city': 'Riga', 'country': 'Latvia', 'facility': "Children's Clinical University Hospital", 'geoPoint': {'lat': 56.946, 'lon': 24.10589}}, {'zip': '50009', 'city': 'Kaunas', 'country': 'Lithuania', 'facility': 'Kaunas Clinics Public Institution; Clinic of Nephrology', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'zip': '92288', 'city': 'Klaipėda', 'country': 'Lithuania', 'facility': 'Klaipeda University Hospital; Public Institution', 'geoPoint': {'lat': 55.7068, 'lon': 21.13912}}, {'zip': '76231', 'city': 'Šiauliai', 'country': 'Lithuania', 'facility': 'Siauliai Republican Hospital Public Institution', 'geoPoint': {'lat': 55.93333, 'lon': 23.31667}}, {'zip': '08661', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '08661', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Vilnius University Hospital Santariskiu Clinic', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '8117', 'city': 'Vilnius', 'country': 'Lithuania', 'facility': 'Republican Tuberculosis and Infectious Diseases University H', 'geoPoint': {'lat': 54.68916, 'lon': 25.2798}}, {'zip': '54769', 'city': 'Cuautitlán Izcalli', 'country': 'Mexico', 'facility': 'Phylaxis Clinical Research S de RL de CV', 'geoPoint': {'lat': 19.64388, 'lon': -99.21598}}, {'zip': '44280', 'city': 'Guadalajara', 'country': 'Mexico', 'facility': 'Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde; Infectología piso 7', 'geoPoint': {'lat': 20.67738, 'lon': -103.34749}}, {'zip': '03720', 'city': 'México', 'country': 'Mexico', 'facility': 'Centro de Investigacion Clínica GRAMEL S.C', 'geoPoint': {'lat': 31.00435, 'lon': -108.15213}}, {'zip': '14000', 'city': 'México', 'country': 'Mexico', 'facility': 'Instituto Nacional de Ciencias Medicas y Nutricion Salvador; Infectologia', 'geoPoint': {'lat': 31.00435, 'lon': -108.15213}}, {'zip': '14080', 'city': 'México', 'country': 'Mexico', 'facility': 'INER- Instituto Nacional de Enfermedades Respiratorias"Ismae', 'geoPoint': {'lat': 31.00435, 'lon': -108.15213}}, {'zip': '64040', 'city': 'Monterrey', 'country': 'Mexico', 'facility': 'Hospital Universitario de Monterrey; Infectologia', 'geoPoint': {'lat': 25.68435, 'lon': -100.31721}}, {'zip': '45116', 'city': 'Zapopan', 'country': 'Mexico', 'facility': 'Hospital de Especialidades del Centro Medico Puerta de Hierr', 'geoPoint': {'lat': 20.72111, 'lon': -103.38742}}, {'zip': '15-540', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Wojewodzki Szp.Specjalistyczny im.K.Dluskiego w Bialymstoku', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '85-079', 'city': 'Bydgoszcz', 'country': 'Poland', 'facility': 'NZOZ Vitamed', 'geoPoint': {'lat': 53.1235, 'lon': 18.00762}}, {'zip': '80-214', 'city': 'Gdansk', 'country': 'Poland', 'facility': 'Uniwersyteckie Centrum Kliniczne', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '31-501', 'city': 'Krakow', 'country': 'Poland', 'facility': 'SPZOZ Szpital Uniw W Krakowie', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '90-153', 'city': 'Lodz', 'country': 'Poland', 'facility': 'SPZOZ Uniwersytecki Szp Klin; nr1 im.N.Barlickiego UM', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '70-111', 'city': 'Szczecin', 'country': 'Poland', 'facility': 'SPSK nr 2 Pomorskiej Akademii Medycznej w Szczecinie', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}, {'zip': '02-006', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Szpital Dzieciatka Jezus-Centrum Lecezenia Obrazen; Dpt of Transplantation Medicine & Nephrology', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '04-730', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Instytut Pomnik-Centrum Zdrowia Dziecka, Klinika Nefrologii, Transp. Nerek i Nadcisnienia Tetniczego', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '50-367', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'SP Szpital Kliniczny Nr 1 we Wroclawiu', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '50-445', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'ALL-MED Specjalistyczna Opieka Medyczna', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '022328', 'city': 'Bucharest', 'country': 'Romania', 'facility': 'Institutul de Urologie Si Transplant Renal Fundeni', 'geoPoint': {'lat': 44.43225, 'lon': 26.10626}}, {'zip': '9301', 'city': 'Bloemfontein', 'country': 'South Africa', 'facility': 'Josha Research', 'geoPoint': {'lat': -29.12107, 'lon': 26.214}}, {'zip': '4001', 'city': 'Durban', 'country': 'South Africa', 'facility': 'Londisizwe Research Centre', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '4001', 'city': 'Durban', 'country': 'South Africa', 'facility': 'Sebastian Peter', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '4092', 'city': 'Durban', 'country': 'South Africa', 'facility': 'Dr V Naidoo Private Practice', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '4096', 'city': 'Durban', 'country': 'South Africa', 'facility': 'Govind U', 'geoPoint': {'lat': -29.8579, 'lon': 31.0292}}, {'zip': '1818', 'city': 'Johannesburg', 'country': 'South Africa', 'facility': 'Soweto CTC - Dr Phoshoko site', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '1983', 'city': 'Johannesburg', 'country': 'South Africa', 'facility': 'Soweto CTC - Dr Mushwana site', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '2113', 'city': 'Johannesburg', 'country': 'South Africa', 'facility': 'Newtown Clinical Research', 'geoPoint': {'lat': -26.20227, 'lon': 28.04363}}, {'zip': '1055', 'city': 'Middelburg', 'country': 'South Africa', 'facility': 'Mzansi Ethical Research Centre', 'geoPoint': {'lat': -25.77507, 'lon': 29.46482}}, {'zip': '7626', 'city': 'Paarl', 'country': 'South Africa', 'facility': 'Be Part Yoluntu Centre', 'geoPoint': {'lat': -33.73378, 'lon': 18.97523}}, {'zip': '6020', 'city': 'Port Elizabeth', 'country': 'South Africa', 'facility': 'Global Clinical Trials Port Elizabeth', 'geoPoint': {'lat': -33.96109, 'lon': 25.61494}}, {'zip': '0002', 'city': 'Pretoria', 'country': 'South Africa', 'facility': 'Kalafong Hospital; Pathology', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '0084', 'city': 'Pretoria', 'country': 'South Africa', 'facility': 'Emmed Research', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '0112', 'city': 'Pretoria', 'country': 'South Africa', 'facility': 'Synexus Clinical Research Centres SA Stanza Bopape', 'geoPoint': {'lat': -25.74486, 'lon': 28.18783}}, {'zip': '1818', 'city': 'Soweto', 'country': 'South Africa', 'facility': 'Soweto Clinical Trial Centre', 'geoPoint': {'lat': -26.26781, 'lon': 27.85849}}, {'zip': '7505', 'city': 'Tygerberg; Cape Town', 'country': 'South Africa', 'facility': 'Tygerberg Hospital Pediatrics and Child Health'}, {'zip': '9460', 'city': 'Welkom', 'country': 'South Africa', 'facility': 'Welkom Clinical Trial Centre', 'geoPoint': {'lat': -27.97742, 'lon': 26.73506}}, {'zip': '08907', 'city': "L'Hospitalet de Llobregat", 'state': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Universitari de Bellvitge; Servicio de Nefrologia', 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'state': 'LA Coruña', 'country': 'Spain', 'facility': 'Hospital Clinico Universitario de Santiago', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': "Hospital Universitari Vall d'Hebron; Departamento de Enfermedades Infecciosas", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': "Hospital Universitari Vall d'Hebron", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Clínic i Provincial; Servicio de Hematología y Oncología', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28007', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital General Universitario Gregorio Marañon', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28009', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Infantil Universitario Nino Jesus', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Clinico San Carlos; Servicio de Nefrologia', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Clínico San Carlos; Servicio de Enfermedades Infecciosas', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre; HIV Unit', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre; Servicio de Pediatria', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario La Paz; Hepatología y Trasplantes', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28046', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario la Paz; Servicio de Enfermedades Infecciosas - HIV unit', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '8091', 'city': 'Zurich', 'country': 'Switzerland', 'facility': 'Universitätsspital Zürich; Klinik für Nephrologie', 'geoPoint': {'lat': 47.36667, 'lon': 8.55}}, {'zip': '01135', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'Ukrainian Pediatric Specialized Hospital of Ministry of Health of Ukraine Dept of BMT', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04050', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'Institute of Nephrology AMS; Dept of Nephrology & dialysis', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '91045', 'city': 'Lugnansk', 'country': 'Ukraine', 'facility': 'Lugansk Regional Clinical Hospital; Chair of Therapy Faculty of Postgr.Ed'}, {'zip': '69600', 'city': 'Zaporizhzhya', 'country': 'Ukraine', 'facility': 'Zaporozhye State Medical University; Dept of Transplantology', 'geoPoint': {'lat': 47.85167, 'lon': 35.11714}}, {'zip': 'BS2 8BJ', 'city': 'Bristol', 'country': 'United Kingdom', 'facility': 'University Hospitals Bristol NHS Foundation Trust', 'geoPoint': {'lat': 51.45523, 'lon': -2.59665}}, {'zip': 'M13 9WL', 'city': 'Manchester', 'country': 'United Kingdom', 'facility': 'Manchester Royal Infirmary; Renal Transplant Unit', 'geoPoint': {'lat': 53.48095, 'lon': -2.23743}}, {'zip': 'NG5 1PB', 'city': 'Nottingham', 'country': 'United Kingdom', 'facility': 'Nottingham City Hospital; Transplant Unit', 'geoPoint': {'lat': 52.9536, 'lon': -1.15047}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-La Roche'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}